Jump to the main content block

Prof. De-Ching Chang, Gene therapy for metastatic prostate cancer using JCPyV VLPs as the gene delivery vector.



To investigate whether PSAtk-VLPs inhibited the growth of metastasized prostate cancer cells, we established an animal model of bone-metastatic prostate cancer to compare the efficacy and effectiveness of PSAtk-VLPs with leuprorelin acetate and enzalutamide, a hormonal agent commonly used in clinical settings. We observed that PSAtk-VLPs effectively inhibited the growth of bone metastasized prostate cancer cells in the animal model. In addition, PSAtk-VLPs showed a higher effectiveness than hormone therapy in this animal model. These results suggested that PSAtk-VLPs may serve as a treatment option for mCRPC therapy in the future.

Click Num: